MeiraGTx (NASDAQ:MGTX) vs. Omeros (NASDAQ:OMER) Head to Head Contrast

MeiraGTx (NASDAQ:MGTX) and Omeros (NASDAQ:OMER) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, dividends, analyst recommendations and valuation.

Institutional and Insider Ownership

67.5% of MeiraGTx shares are held by institutional investors. Comparatively, 48.8% of Omeros shares are held by institutional investors. 7.4% of MeiraGTx shares are held by company insiders. Comparatively, 10.5% of Omeros shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares MeiraGTx and Omeros’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
MeiraGTx	19.87%	283.85%	29.39%
Omeros	N/A	-164.92%	69.41%

Risk & Volatility

MeiraGTx has a beta of 1.09, meaning that its share price is 9% more volatile than the S&P 500. Comparatively, Omeros has a beta of 2.96, meaning that its share price is 196% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for MeiraGTx and Omeros, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MeiraGTx	0	3	5	0	2.62
Omeros	0	2	3	0	2.60

MeiraGTx currently has a consensus price target of $24.00, suggesting a potential upside of 166.67%. Omeros has a consensus price target of $30.33, suggesting a potential upside of 79.28%. Given MeiraGTx’s stronger consensus rating and higher probable upside, research analysts plainly believe MeiraGTx is more favorable than Omeros.

Valuation and Earnings

This table compares MeiraGTx and Omeros”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MeiraGTx	$81.39 million	10.62	-$114.20 million	$0.71	12.68
Omeros	$38.42 million	31.88	-$3.35 million	$1.28	13.22

Omeros has lower revenue, but higher earnings than MeiraGTx. MeiraGTx is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks.

About MeiraGTx

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company’s products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.